Last reviewed · How we verify

Drug resistant tuberculosis — Treatment Landscape & Competitive Intelligence

Drug resistant tuberculosis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Drug resistant tuberculosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Sirturo bedaquiline Janssen Therap Diarylquinoline Antimycobacterial Potassium voltage-gated channel subfamily H member 2 2012-01-01
Deltyba delamanid Pfizer Inc. delamanid

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Janssen Therap · 1 drug in Drug resistant tuberculosis
  2. Pfizer Inc. · 1 drug in Drug resistant tuberculosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Drug resistant tuberculosis:

Cite this brief

Drug Landscape (2026). Drug resistant tuberculosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/drug-resistant-tuberculosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing